Reports Q4 revenue $34.23M vs. 30.03M last year. “In the Q4, Heron saw continued positive momentum and an increased sales trajectory in both our acute care and oncology care franchises, illustrating how the strategic decisions made over the past year have positioned the Company for long-term success and profitability,” said Craig Collard, CEO. “I am pleased to share this quarterly update and look forward to building upon what we achieved in the Q4, providing substantial value and meaningful solutions in the acute care and oncology care settings.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HRTX:
- Options Volatility and Implied Earnings Moves Today, March 12, 2024
- Heron Therapeutics Inc (HRTX) Q4 Earnings Cheat Sheet
- Biotech Alert: Searches spiking for these stocks today
- Heron Therapeutics Gains FDA Nod for ZYNRELEF® Expansion
- Heron Therapeutics announces FDA approval of ZYNRELEF indication expansion
